Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
(OCL) ZUG, Switzerland, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session
What timeline and probability are associated with regulatory approval and potential market launch following the conference presentations?
What are the competitive implications of these results compared to other companies developing treatments for diabetic macular edema and acute optic neuritis?
How will the Phase 2 ACUITY trial results for Privosegtor affect Oculis' valuation and near-term stock volatility?
15 days ago